P872: PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis – A Randomised Controlled TrialECCO'24Year: 2024
Authors: Choy, M.(1,2)*;Li Wai Suen, C.F.D.(1,2);Con, D.(1);Boyd, K.(1);Pena, R.(1);Burrell, K.(1);Rosella, O.(1);Proud, D.(3);Brouwer, R.(3);Gorelik, A.(4);Liew, D.(5);Connell, W.(6);Wright, E.(6);Taylor, K.(7);Pudipeddi, A.(8);Sawers, M.(9);Christensen, B.(10);Ng, W.(11);Begun, J.(12);Radford-Smith, G.(13);Garg, M.(14);Martin, N.(15);Van Langenberg, D.R.(16);Ding, N.S.(6);Beswick, L.(9);Leong, R.W.(8);Sparrow, M.P.(7);De Cruz, P.(1,2);
(1)Austin Health, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Austin Academic Centre, Melbourne, Australia;(3)Austin Health, Department of Colorectal Surgery, Melbourne, Australia;(4)University of Melbourne, Department of Medicine, Melbourne, Australia;(5)University of Adelaide, Department of Medicine, Adelaide, Australia;(6)St Vincent@E@s Hospital, Department of Gastroenterology, Melbourne, Australia;(7)Alfred Health, Department of Gastroenterology, Melbourne, Australia;(8)Concord Hospital, Department of Gastroenterology, Sydney, Australia;(9)Barwon Health, Department of Gastroenterology, Geelong, Australia;(10)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(11)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(12)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(13)Royal Brisbane and Women@E@s Hospital, Department of Gastroenterology, Brisbane, Australia;(14)Northern Health, Department of Gastroenterology, Melbourne, Australia;(15)Princess Alexandra Hospital, Department of Gastroenterology, Brisbane, Australia;(16)Eastern Health, Department of Gastroenterology, Melbourne, Australia;
P873: Ustekinumab Real World Evidence Study (UndieS): Assessing the suitability of patients treated in routine clinical care for participation in the pivotal phase 3 clinical trialECCO'24Year: 2024
Authors: Young, D.(1,2);Booker, C.(3);Batchelor, J.(2);Bodger, K.(4);Cummings, F.(2,3)*;
(1)University Hospital Southampton NHS Foundation Trust, Pharmacy Department, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom;(4)University of Liverpool, Department of Health Data Science, Liverpool, United Kingdom;On behalf of the UndieS studygroup
P874: Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD studyECCO'24Year: 2024
Authors: Colombel, J.F.(1)*;Danese, S.(2);Schreiber, S.(3);Sands, B.E.(1);Yarur, A.(4);Kim, D.H.(5);Lee, Y.N.(5);Hanauer, S.B.(6);
(1)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(3)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(4)Cedars Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute, Los Angeles, United States;(5)Celltrion Healthcare Co.- Ltd, Not applicable, Incheon, Korea- Republic Of;(6)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago, United States;
P875: Filgotinib in ulcerative colitis: early real-world multicentre UK experienceECCO'24Year: 2024
Authors: Young, D.(1,2)*;Rahmany, S.(1);Taylor, D.(1);Davis, E.(3);Campbell, R.(4);Hazel, K.(5);Sethi-Arora , K.(6);Ritchie, S.(7);Dhar, A.(7,8);Limdi, J.(6,9);Cooney, R.(5);Seenan, J.P.(4);Walsh, A.(3);Cummings, F.(1,2);
(1)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)Oxford University Hospitals NHS Foundation Trust, Gastroenterology, Oxford, United Kingdom;(4)NHS Greater Glasgow & Clyde, Gastroenterology, Glasgow, United Kingdom;(5)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(6)Northern Care Alliance NHS Foundation Trust, Gastroenterology, Greater Manchester, United Kingdom;(7)County Durham & Darlington NHS Foundation Trust, Gastroenterology, Darlington, United Kingdom;(8)Teesside University, School of Medicine, Middlesbrough, United Kingdom;(9)University of Manchester, School of Medical Sciences, Manchester, United Kingdom;
P876: Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis - results from multi-center, double-blind, randomized, placebo-controlled clinical study.ECCO'24Year: 2024
Authors: KarlowiczMD, K.(1)*;Lewandowski, K.(1);Tulewicz-Marti, E.(1);Domżał-Magrowska, D.(2);Talar-Wojnarowska, R.(2);Małecka – Wojciesko, E.(2);Rydzewska, G.(1,3);
(1)National Medical Institute of the Ministry of the Interior and Administration, Clinical Department of Internal Medicine and Gastroenterology, Warsaw, Poland;(2)Medical University of Lodz, Department of Digestive Tract Diseases, Lodz, Poland;(3)Jan Kochanowski University, Collegium Medicum, Kielce, Poland;
P877: A comparison of vedolizumab and ustekinumab treatment in patients with Ulcerative Colitis after failure of treatment with tumor necrosis factor inhibitorECCO'24Year: 2024
Authors: Helm Wiken, T.E.(1,2)*;Høivik, M.L.(1,2);Buer, L.(1);Warren, D.J.(3);Bolstad, N.(3);Anisdahl, K.(1,2);Lundekvam, J.(1,2);Hagen, M.(1,2,4);Medhus, A.W.(1,2);
(1)Oslo University Hospital, Gastroenterology, Oslo, Norway;(2)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(3)Oslo University Hospital, Medical Biochemistry, Oslo, Norway;(4)Oslo Metropolitan University, Faculty of Health Sciences, Oslo, Norway;
P878: Assessment of Ulcerative Colitis Relapse Risk Using RDI (Red Dichromatic Imaging)ECCO'24Year: 2024
Authors: Hashimoto, Y.(1)*;Itoi, Y.(1);Tomaru, S.(1);Sato, K.(1);Tanaka, H.(1);Shiko, K.(1);Yoji, T.(1);Uraoka, T.(1);
(1)Gunma University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Gunma, Japan;
P879: Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysisECCO'24Year: 2024
Authors: Shehab, M.(1)*;Alrashed, F.(2);Alsayegh, A.(1);Aldallal , U.(1);Ma, C.(3);Narula, N.(4);Jairath, V.(5);Singh, S.(6);Bessissow, T.(7);
(1)Mubarak Al-Kabeer Hospital, Internal medicine, Kuwait, Kuwait;(2)Kuwait University, Pharmacy Practice, Kuwait, Kuwait;(3)Departments of Medicine and Community Health Sciences, Internal medicine, Calgary, Canada;(4)McMaster University, Internal medicine, Hamilton, Canada;(5)Western University, Internal medicine, London, Canada;(6)University of California, Internal medicine, San Diego, United States;(7)McGill University, Internal medicine, Montreal, Canada;
P880: The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s programECCO'24Year: 2024
Authors: Pipicella, J.L.(1,2,3)*;McNamara, J.(4,5);Wilson, W.(6,7);Lynch, K.(8,9);Walker, G.(10);Begun, J.(11,12);Lawrance, I.(13,14);Ghaly, S.(15);Radford-Smith, G.(16,17,18);Williams, A.J.(1,3,4);Gearry, R.(19);Schultz, M.(20);Brett, L.(21);Andrews, J.M.(2,8,22);Connor, S.J.(1,3,4,23);
(1)University of New South Wales, Medicine & Health South Western Sydney Clinical School, Warwick Farm, Australia;(2)Crohn@E@s Colitis Cure, CCCure, Pyrmont, Australia;(3)Ingham Institute for Applied Medical Research, Gastroenterology- Hepatology and Inflammatory Bowel Disease Research Group, Liverpool, Australia;(4)Liverpool Hospital, Gastroenterology and Hepatology, Liverpool, Australia;(5)Ingham Institute for Applied Medical Research, Gastroenterology-epatology and Inflammatory Bowel Disease Research Group, Liverpool, Australia;(6)Lyell McEwin Hospital, Anaesthetics, Adelaide, Australia;(7)SA Health, Chief Medical Information Officer, Adelaide, Australia;(8)Central Adelaide Local Health Network, Gastroenterology, Adelaide, Australia;(9)University of Adelaide, Faculty of Health and Medical Sciences, Adelaide, Australia;(10)Royal Brisbane and Women@E@s Hospital, Gastroenterology & Hepatology, Herston, Australia;(11)Mater Hospital, Gastroenterology, South Brisbane, Australia;(12)The University of Queensland, Faculty of Medicine, St Lucia, Australia;(13)St John of God Health Care, Gastroenterology, Subiaco, Australia;(14)The University of Western Australia, Medical School- Internal Medicine, Perth, Australia;(15)St Vincent@E@s Hospital Sydney, Gastroenterology, Darlinghurst, Australia;(16)QIMR Berghofer Medical Research Institute, Gut Health, Herston, Australia;(17)Integrated Gut Health, Gastroenterology, Taringa, Australia;(18)Royal Brisbane and Women’s Hospital, Gastroenterology & Hepatology, Herston, Australia;(19)University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand;(20)Dunedin Hospital, Gastroenterology, Dunedin, New Zealand;(21)Logan Hospital, Gastroenterology, Meadowbrook, Australia;(22)The University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(23)Crohn’s Colitis Cure, CCCure, Pyrmont, Australia;
P881: Real-life vs trial access to biologic therapy differences: a 2019-2020 experience in an Italian tertiary IBD center.ECCO'24Year: 2024
Authors: DI VINCENZO, F.(1)*;Maresca, R.(1);Mora, V.(1);Petito, V.(1);Turchini, L.(1);Amatucci, V.(1);Napolitano, D.(1);Schiavoni, E.(1);Lopetuso, L.R.(1);Parisio, L.(1);Settanni, C.R.(1);Pizzoferrato, M.(1);Armuzzi, A.(2);Pugliese, D.(1);Laterza, L.(1);Gasbarrini, A.(1);Scaldaferri, F.(1);
(1)Fondazione Policlinico Universitario @D@A. Gemelli@D@ IRCCS- Università Cattolica del Sacro Cuore, Dipartimento di Medicina Interna e Gastroenterologia, Roma, Italy;(2)Humanitas Research Hospital- IRCCS, IBD center, Roma, Italy;
P882: A Phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s DiseaseECCO'24Year: 2024
Authors: Swaroop, S.(1)*;Vuyyuru, S.(1);Kante, B.(2);Kumar, P.(1);Mundhra, S.(1);Arora, U.(1);Goyal, A.(3);Kandasamy, D.(3);Sharma, R.(3);Kabilan, K.(3);Kedia, S.(1);Dash, N.(4);Ahuja, V.(1);
(1)All India Institute of Medical Sciences- New Delhi, Gastroenterology, New Delhi, India;(2)KIMS Hospitals, Gastroenterology, Hyderabad, India;(3)All India Institute of Medical Sciences- New Delhi, Department of Radiodiagnosis and Interventional Radiology, New Delhi, India;(4)All India Institute of Medical Sciences- New Delhi, Gastrointestinal Surgery, New Delhi, India;
P883: Impaired long-term quantitative cellular response to SARS-COV-2 vaccine in thiopurine-treated IBD patientsECCO'24Year: 2024
Authors: Mayorga Ayala, L.F.(1)*;Herrera-deGuise, C.(1);Esperalba, J.(2);Martinez-Gomez, X.(3);Céspedes Martinez, E.(1);Serra Ruiz, X.(1);Robles, V.(1);Lastiri, E.(1);Perez, Z.(1);Oller, E.(1);Fernandez-Naval, C.(2);Martinez-Gallo, M.(4);Casellas, F.(1);Borruel, N.(1);
(1)Vall d@E@Hebron University Hospital, Inflammatory Bowel Disease Unit- Gastroenterology Dept, Barcelona, Spain;(2)Vall d@E@Hebron University Hospital, Servei de Microbiologia- Universitat Autònoma de Barcelona UAB, Barcelona, Spain;(3)Vall d@E@Hebron University Hospital, Servei de Medicina Preventiva i Epidemiologia, Barcelona, Spain;(4)Vall d@E@Hebron University Hospital, Servei d@E@Immunologia- Vall d@E@Hebron Institut de Recerca VHIR- Universitat Autònoma de Barcelona UAB, Barcelona, Spain;
P884: Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life studyECCO'24Year: 2024
Authors: Bouguen, G.(1)*;Gossec, L.(2);Abitbol, V.(3);Senbel, E.(4);Bonnaud, G.(5);Roblin, X.(6);Bouhnik, Y.(7);Nancey, S.(8);Mathieu, N.(9);Filippi, J.(10);Vuitton, L.(11);Nahon, S.(12);Dellal, A.(13);Denis, A.(14);Habauzit, C.(14);Benkhalifa, S.(14);Marotte, H.(15);
(1)CHU de Rennes, Maladies de l@E@appareil digestif, Rennes, France;(2)Sorbonne Université and Pitié-Salpêtrière Hospital, Rheumatology, Paris, France;(3)Cochin Hospital, Hepato-Gastroenterology, Paris, France;(4)Private Practice, Rheumatology, Marseille, France;(5)Private Practice, Hepato-gastroenterology, Toulouse, France;(6)CHU Saint-Etienne, Hepato-gastroenterology, Saint-Etienne, France;(7)Institut des MICI, Hepato-gastroenterology, Neuilly-sur-Seine, France;(8)CHU Lyon, Hepato-gastroenterology, Lyon, France;(9)CHU Grenoble, Hepato-gastroenterology, Grenoble, France;(10)Private Practice, Hepato-gastroenterology, Cagnes-sur-Mer, France;(11)CHU Besançon, Hepato-gastroenterology, Besançon, France;(12)CHI Montfermeil, Hepato-gastroenterology, Montfermeil, France;(13)CHI Montfermeil, Rheumatology, Montfermeil, France;(14)Celltrion Healthcare France, Medical, Issy les Moulineaux, France;(15)CHU Saint-Etienne, Rheumatology, Saint-Etienne, France;
P885: Pharmacokinetics, pharmacodynamics, and immunogenicity of biosimilar infliximab in pediatric patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Dipasquale, V.(1)*;Alibrandi, A.(2);Pellegrino, S.(1);Ramistella, V.(1);Romano, C.(1);
(1)University Hospital of Messina, Department of Human Pathology in Adulthood and Childhood @D@G. Barresi@D@, Messina, Italy;(2)University of Messina, Department of Economics, Messina, Italy;
P886: Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel diseaseECCO'24Year: 2024
Authors: Serra-Ruiz, X.(1)*;Céspedes Martínez, E.(1);Mayorga Ayala, L.(1);Herrera de-Guise, C.(1);Robles Alonso, V.(1);Pérez Martínez, Z.(1);Oller, E.(1);Borruel Sainz, N.(1);
(1)Crohn’s and Colitis Unit- Hospital Universitari Vall d’Hebron, Gastroenterology Department, Barcelona, Spain;
P888: Effectiveness and safety of Adalimumab Biosimilars in Bio-naive patients with Inflammatory Bowel Disease: The Galician experienceECCO'24Year: 2024
Authors: Vega Villaamil, P.(1)*;Vázquez Rey, M.T.(2);Bastón Rey, I.(3);Ayude Galego, M.(4);Carmona Campos, A.(5);Baz López, A.M.(6);Molina Arriero, G.(7);Ruiz Barcia, M.J.(8);Regueiro Expósito, C.(9);
(1)Complexo Hospitalario Universitario de Ourense, Gastroenterology department, OURENSE, Spain;(2)Complexo Hospitalario Universitario A Coruña, Gastroenterology department, A Coruña, Spain;(3)Hospital Universitario Clínico de Santiago, Gastroenterology department, Santiago de Compostela, Spain;(4)Complexo Hospitalario Universitario de Vigo, Gastroenterology department, Vigo, Spain;(5)Hospital Ribera Povisa, Gastroenterology department, Vigo, Spain;(6)Complexo Hospitalario Universitario Lucus Augusti, Gastroenterology department, Lugo, Spain;(7)Complexo Hospitalario Universitario de Ferrol, Gastroenterology department, Ferrol, Spain;(8)Hospital da Costa, Gastroenterology department, Burela, Spain;(9)Galicia Sur Health Research Institute, Research Group in Gastrointestinal Oncology, Ourense, Spain;
P889: Facilitating equitable IBD care trust-wide: a need for treatment targets in IBD?ECCO'24Year: 2024
Authors: Hentges, M.(1)*;Ibarra, A.(1);Onyl Ronquillo, F.(1);Gnanasampanthan, S.(1);O’Shea, I.(1);Utulu, S.(1);Vlachou, F.(1);Gordon, H.(1);Jawad, N.(1);
(1)Barts Health NHS Trust, Gastroenterology, London, United Kingdom;
P890: Usefulness of subcutaneous Infliximab in patients with Inflammatory Bowel Disease in clinical practice: are increased levels associated with clinical benefit?ECCO'24Year: 2024
Authors: Garcia De La Filia Molina, I.(1)*;Mesonero Gismero, F.(1);López Cardona, J.(1);Sánchez Aldehuelo, R.(1);De la Serna Gamboa, Á.(1);Gramage Caro, T.(2);Fernández Fernández, C.(1);Garbiñe , R.A.(3);Agustín , A.M.(1);López San Román, A.(1);
(1)Ramon y Cajal Hospital, Gastroenterology, Madrid, Spain;(2)Ramon y Cajal Hospital, Pharmacology, Madrid, Spain;(3)Ramon y Cajal Hospital, Immunology, Madrid, Spain;
P891: Comparative Effectiveness and Safety of Infliximab and Tacrolimus in the Treatment of Acute Severe Ulcerative ColitisECCO'24Year: 2024
Authors: Cohen, N.A.(1,2)*;Tamir-Degabli, N.(1,2);Rozenfeld, A.(1,2);Hirsch, A.(1,2);Thurm, T.(1,2);Ron, Y.(1,2);Fishman, S.(1,2);Leibovitzh, H.(1,2);Maharshak, N.(1,2);
(1)Tel Aviv Medical Center, IBD Center- Section of Gastroenterology- Hepatology and Nutrition, Tel Aviv, Israel;(2)Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel;
